In asthma January 1997, 62 subjects who had been the placebos in the 1995 study were invited to receive the vitamin B12. In June 1997, the 62 placebo subjects were sent alternative a questionnaire asking: How would you compare treatment your overall allergy (hay fever) symptoms asthma this spring alternative to the last two springs? 20 people responded, with 15 reporting having had the B12 treatment, and 5 not. 12 of the 15 reported at least a slight improvement in overall allergy symptoms, and 1 of the 5. Improvement ratios - 12:3 having received treatment, 1:4 not having received treatment treatment.8 A bioequivalence study showed that a 3000 mcg asthma lozenge delivered an equivalent amount of cyanocobalamin to the blood as a 15 mcg alternative injection.9 From the spring to the summer patients with demonstrated allergic rhinitis received with the cyanocobalamin (or placebo) containing treatment lozenge twice daily for 21 consecutive days. All subjects also received C and asthma B oral multivitamins for 21 days. Twice daily subjects maintained a nine-week diary on sneezing, runny nose, nasal congestion, itchy eyes, itchy nose and antihistamine (chlorpheniramine) alternative and treatment use. In the post-treatment period, asthma the active group alternative (n=15) recorded on average a greater treatment reduction in symptoms and in antihistamine use than the placebo group (n=9). The results yielded reductions (0.1>p>0.01) asthma in total weekly symptom/rescue medication for the active group compared alternative to the placebo for weeks 2, 6, 8 and 9. The results tend to replicate those treatment of the studies on injectable asthma cyanocobalamin.10

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls alternative reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points treatment of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics asthma indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, alternative Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did treatment not develop in the second metabisulfite challenge.6

©2003 www.asian-homeopathic-remedies.com All rights reserved.